library(MBNMAdose) #devtools::load_all() library(rmarkdown) library(knitr) library(dplyr) knitr::opts_chunk$set( collapse = TRUE, comment = "#>", fig.width = 7, fig.height = 5, include=TRUE, tidy.opts=list(width.cutoff=80), tidy=TRUE )
Before embarking on an analysis, the first step is to have a look at the
raw data. Two features (network connectivity and dose-response
relationship) are particularly important for MBNMA. For this we want to
get our dataset into the right format for the package. We can do this
using mbnma.network()
.
# Using the triptans dataset network <- mbnma.network(triptans) summary(network)
This function takes a dataset with the columns:
studyID
Study identifiersagent
Agent identifiers (can be character, factor or numeric)dose
Numeric data indicating the dose of the given agent within
the study armclass
An optional column indicating a particular class code.
Agents with the same name/identifier must also have the same class
code.Depending on the type of data (and the likelihood) the following columns are required:
y
Numeric data indicating the mean response for a given study
armse
Numeric data indicating the standard error for a given
study armr
Numeric data indicating the number of responders in a given
study armn
Numeric data indicating the total number of participants in
a given study armr
Numeric data indicating the number of events in a given
study armE
Numeric data indicating the total exposure time in a given
study armIt then performs the following checks on the data:
Finally it converts the data frame into an object of
class("mbnma.network")
, which contains indices for study arms, numeric
variables for treatments, agents and classes, and stores a vector of
treatment, agent and class names as an element within the object. By
convention, agents are numbered alphabetically, though if the original
data for agents is provided as a factor then the factor codes will be
used. This then contains all the necessary information for subsequent
MBNMAdose
functions.
Examining how the evidence in the network is connected and identifying which studies compare which treatments/agents helps to understand which effects can be estimated, what information will be helping to inform those estimates, and whether linking via the dose-response relationship is possible if the network is disconnected at the treatment-level. The complexity of dose-response relationships that can be estimated is dependent on the number of doses of each agent available, so this is also important to know.
Network plots can be plotted which shows which treatments/agents have
been compared in head-to-head trials. Typically the thickness of
connecting lines ("edges") is proportional to the number of studies that
make a particular comparison and the size of treatment nodes
("vertices") is proportional to the total number of patients in the
network who were randomised to a given treatment/agent (provided N
is
included as a variable in the original dataset for mbnma.network()
).
In MBNMAdose
these plots are generated using igraph
, and can be
plotted by calling plot()
. The generated plots are objects of
class("igraph")
meaning that, in addition to the options specified in
plot()
, various igraph
functions can subsequently be used to make
more detailed edits to them.
Within these network plots, vertices are automatically aligned in a circle (as the default) and can be tidied by shifting the label distance away from the nodes.
# Prepare data using the triptans dataset tripnet <- mbnma.network(triptans) summary(tripnet) # Draw network plot plot(tripnet)
If some vertices are not connected to the network reference treatment through any pathway of head-to-head evidence, a warning will be given. The nodes that are coloured white represent these disconnected vertices.
# Prepare data using the gout dataset goutnet <- mbnma.network(gout) summary(goutnet)
plot(goutnet, label.distance = 5)
However, whilst at the treatment-level (specific dose of a specific agent), many of these vertices are disconnected, at the agent level they are connected (via different doses of the same agent), meaning that via the dose-response relationship it is possible to estimate results.
# Plot at the agent-level plot(goutnet, level="agent", label.distance = 6)
One agent (RDEA) is still not connected to the network, but MBNMAdose
allows agents to connect via a placebo response even if they do not
include placebo in a head-to-head trial (see [Linking disconnected
treatments via the dose-response relationship]).
# Plot connections to placebo via a two-parameter dose-response function (e.g. Emax) plot(goutnet, level="agent", doselink = 2, remove.loops = TRUE, label.distance = 6)
It is also possible to plot a network at the treatment level but to colour the doses by the agent that they belong to.
# Colour vertices by agent plot(goutnet, v.color = "agent", label.distance = 5)
Several further options exist to allow for inclusion of disconnected treatments, such as assuming some sort of common effect among agents within the same class. This is discussed in more detail later in the vignette.
In order to consider which functional forms may be appropriate for
modelling the dose-response relationship, it is useful to look at
results from a "split" network meta-analysis (NMA), in which each dose
of an agent is considered as separate and unrelated (i.e. we are not
assuming any dose-response relationship). The nma.run()
function
performs a simple NMA, and by default it drops studies that are
disconnected at the treatment-level (since estimates for these will be
very uncertain if included).
# Run a random effect split NMA using the alogliptin dataset alognet <- mbnma.network(alog_pcfb) nma.alog <- nma.run(alognet, method="random")
print(nma.alog) # Draw plot of NMA estimates plotted by dose plot(nma.alog)
In the alogliptin dataset there appears to be a dose-response relationship, and it also appears to be non-linear.
One additional use of nma.run()
is that is can be used after fitting
an MBNMA to ensure that fitting a dose-response function is not leading
to poorer model fit than when conducting a conventional NMA. Comparing
the total residual deviance between NMA and MBNMA models is useful to
identify if introducing a dose-response relationship is leading to
poorer model fit. However, it is important to note that if treatments
are disconnected in the NMA and have been dropped (drop.discon=TRUE
),
there will be fewer observations present in the dataset, which will
subsequently lead to lower pD and lower residual deviance, meaning that
model fit statistics from NMA and MBNMA may not be directly comparable.
Any scripts or data that you put into this service are public.
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.